Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Geron Corporation (GERN)

2.33   0.05 (2.19%) 03-24 16:00
Open: 2.3 Pre. Close: 2.28
High: 2.345 Low: 2.24
Volume: 3,547,658 Market Cap: 1,185(M)

Technical analysis

as of: 2023-03-24 4:26:23 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 3.09     One year: 3.42
Support: Support1: 2.2    Support2: 1.83
Resistance: Resistance1: 2.65    Resistance2: 2.93
Pivot: 2.57
Moving Average: MA(5): 2.34     MA(20): 2.62
MA(100): 2.6     MA(250): 2.17
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 12.2     %D(3): 9.5
RSI: RSI(14): 33.3
52-week: High: 3.83  Low: 1.17
Average Vol(K): 3-Month: 9,287 (K)  10-Days: 7,171 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ GERN ] has closed above bottom band by 17.2%. Bollinger Bands are 21.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.35 - 2.37 2.37 - 2.38
Low: 2.2 - 2.22 2.22 - 2.24
Close: 2.3 - 2.33 2.33 - 2.36

Company Description

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Headline News

Wed, 22 Mar 2023
Geron (GERN) Dips More Than Broader Markets: What You Should ... - Nasdaq

Mon, 20 Mar 2023
Geron Corporation (NASDAQ:GERN) Q4 2022 Earnings Call Transcript - Yahoo Finance

Sat, 18 Mar 2023
Geron (NASDAQ:GERN) Issues Earnings Results - MarketBeat

Fri, 17 Mar 2023
Geron: After Study Results And Q4 Updates, Outlook Still Too ... - Seeking Alpha

Fri, 17 Mar 2023
Geron (NASDAQ:GERN) Now Covered by - MarketBeat

Thu, 16 Mar 2023
Geron (GERN) Q4 2022 Earnings Call Transcript - The Motley Fool

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 509 (M)
% Held by Insiders 4.8072e+008 (%)
% Held by Institutions 0.1 (%)
Shares Short 24,550 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.3826e+008
EPS Est Next Qtl -0.06
EPS Est This Year -0.19
EPS Est Next Year -0.02
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -23
Return on Assets (ttm) 246.6
Return on Equity (ttm) -41.6
Qtrly Rev. Growth 596000
Gross Profit (p.s.) -115.52
Sales Per Share -176.27
EBITDA (p.s.) -1.2009e+008
Qtrly Earnings Growth -0.4
Operating Cash Flow 0 (M)
Levered Free Cash Flow -127 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio -1.4
Price to Book value 0
Price to Sales -0.02
Price to Cash Flow 9.08

Stock Dividends

Dividend 0
Forward Dividend 2.46e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.